EKEkaterina Koledova

Ekaterina Koledova

*This is an algorithmically generated author record based on publicly available information.

Ekaterina Koledova has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adherence and Growth Outcomes in a Large Cohort of Children Treated With Recombinant GH Using a Connected Auto-injector

    by Michel Polak, Natacha Bouhours-Nouet, Paula van Dommelen, Lilian Arnaud, Sophie Berger, Claire Castello-Bridoux, Quentin Le Masne, Mélissande Simonin, Raphaël Untereiner, Viviane Jeanbat, et al.

    Context: Adherence to recombinant GH treatment is crucial to achieve optimal adult height in children with growth disorders. Information on factors responsible for differences in adherence and growth in different countries is limited. Aim: To evaluate adherence and catch-up growth in children receiving GH using Easypod® auto-injectors. Methods: Retrospective cohort analysis of adherence and height, from 481 children (55% boys) in 19 centers in France, from the Growzen® Connect database, from mid-2018 to end-2023. Adherence was classified as high (≥85% of injections) or medium/low ( .5). For children with high adherence, 2-year HSDS gain was significantly higher than for children with lower adherence (0.8 vs +0.5, P = .030). Conclusion: Children using Easypod exhibit high adherence, which aids clinical decision-making and patient engagement. Adherence and catch-up growth decrease with age. Indication for GH treatment had little impact, but overall catch-up growth was significantly greater with high adherence.


  • Open Access

    Monitoring Adherence to Growth Hormone Treatments Using Digital Health Solutions in Hong Kong: An Expert Panel Discussion

    by Antony Fu, Wai Chun Wong, Ekaterina Koledova, Octavio Rivera-Romero, Shabbir Syed-Abdul

    Digital health solutions have evolved for managing long-term treatment with recombinant human growth hormone, making it essential to understand their features and functionalities for adoption and acceptance by healthcare professionals (HCPs), patients and caregivers. Findings from a participatory workshop in Hong Kong explored HCPs’ perspectives on monitoring adherence to growth hormone (GH) therapies using digital health solutions incorporating Aluetta® with Smartdot™ and Growzen™ ecosystem (Merck Healthcare KGaA, Darmstadt, Germany). These insights can empower HCPs to effectively integrate and recommend digital health solutions during GH treatment, fostering successful treatment strategies for patients with growth hormone deficiency.

  • Open Access

    Endocrinologists’ Perceived Benefits and Risks of Digital Transformation for Growth Disorders Care in Taiwan: An Expert Panel Discussion

    by Ekaterina Koledova, Chien-Ming Lin, Ying-Hua Huang, Octavio Rivera-Romero, Shabbir Syed-Abdul

    Digital health technologies have gained acceptance in paediatric growth hormone (GH) therapy, supporting patients and caregivers in their treatment journey with healthcare professionals (HCPs) playing a pivotal role. Understanding HCPs’ perspectives regarding the adoption and recommendation of digital health devices with a connected ecosystem for remote monitoring of real-time adherence is essential for aiding clinical decisions and timely interventions. The results from a participatory workshop in Taiwan involving nine paediatric endocrinologists, exploring the risks and benefits of integrating digital health solutions such as Aluetta® with Smartdot™ and Growzen™ ecosystem (Merck Healthcare KGaA, Darmstadt, Germany) for GH therapy are presented. These findings emphasise the importance of novelty in digitalisation and evidence-based treatment strategies to motivate patients achieve growth improvement.

  • Open Access

    Healthcare Professionals’ Perceptions on Advances in Digital Health Devices for Growth Hormone Therapy: Clinical Expert Panel Discussion in the UK and France

    by Octavio Rivera Romero, Abigail Atterbury, Indraneel Banerjee, Solenn Cochet, Ritika R. Kapoor, Verghese Mathew, Kevin Perge, Pratik Shah, Sally Tollerfield, Marie-Agathe Trouvin, et al.

    Assessing healthcare professionals’ (HCPs’) perceptions on the appropriateness, ease of use and reliability of connected digital health technologies can help to understand acceptance and their recommendations to patients/caregivers for personalization of growth hormone (GH) therapy. Two study cases representing different versions of a digital device were used to facilitate expert panel discussions in the UK and France involving 19 paediatric HCPs. Panel members commented that the new functionalities embodied user-friendly technological progression. The evolution of the easypod device should sustain clinical decision support and enhance personalized approaches to care and management of patients receiving GH therapy.

  • Open Access

    The TUITEK® patient support program improved caregiver-related behaviors on growth hormone treatment adherence

    by Ekaterina Koledova, Pen-Hua Su, Yen-Ju Chen, Aria Assefi, Matias Debicki, Debbie Cooke, Amrit Jheeta, Alexander B. Jones, Jung Eun Moon

    Background: Recombinant human growth hormone (r-hGH) can improve or normalize growth outcomes in pediatric patients with growth hormone deficiency, but poor adherence to the treatment regimen limits treatment effectiveness. TUITEK® is a multicomponent patient support program (PSP) designed to deliver support aimed at behavior change that is personalized to the needs of individual caregivers and patients throughout the treatment care pathway. The aim was to assess the impact of the TUITEK® PSP on knowledge, beliefs and perceptions of adherence to r-hGH treatment in high-risk caregivers.Patients and methods: A prospective pre–post research was conducted across the combined population of caregivers of patients with short stature receiving r-hGH treatment in the TUITEK® PSP in Argentina, South Korea, and Taiwan. Caregivers who were categorized as high-risk based on suboptimal knowledge, beliefs and perceptions of factors influencing adherence to r-hGH treatment (disease and treatment coherence, emotional burden, self-administration, and treatment-related anxiety) were included in the analysis.Results: In total, data from 409 caregivers were available. Involvement in the TUITEK® PSP resulted in a statistically significant (p® PSP. The overall changes were reflected in the changes observed when data were analyzed for individual countries separately.Conclusions: The TUITEK® PSP successfully improved key caregiver-related behaviors that may negatively impact adherence to r-hGH treatment and might improve adherence and therefore clinical outcomes.


  • Open Access

    The Pediatric Growth Hormone Deficiency Patient Journey: Identifying Opportunities for Digital Health Interventions

    by Guido Giunti, Fulvio Michelis, Ammar Halabi, Ekaterina Koledova, Jamie Harvey, Paul Dimitri

    Pediatric growth hormone deficiency (PGHD) is a chronic condition where the pituitary gland fails to produce sufficient growth hormone, leading to delayed growth and developmental challenges. Patient journey maps can provide insight into pain points and potential opportunities for new or improved interventions to enhance care. However, a patient journey map does not yet exist for PGHD. Secondary data analysis was performed on interviews and focus groups from five cohorts in Sweden, the United Kingdom, Luxembourg, France, and The Netherlands. Participants included 62 patients and caregivers who used a prototype digital health solution, which was used to guide discussions. Grounded theory was used to analyze the data, resulting in a patient journey map comprising six stages: awareness, diagnosis, treatment planning, treatment initiation, treatment maintenance and transition. This provides the first detailed PGHD patient journey map, revealing emotional sensitivities and challenges at each stage, and suggesting areas for targeted interventions to improve adherence and long-term outcomes.


  • Open Access

    Healthcare professionals’ perspectives towards the digitalisation of paediatric growth hormone therapies: expert panels in Italy and Korea

    by Octavio Rivera Romero, Hyun Wook Chae, Maria Felicia Faienza, Edoardo Vergani, Chong Kun Cheon, Raffaella Di Mase, Francesco Frasca, Hae Sang Lee, Claudia Giavoli, Jihyun Kim, et al.

    Introduction: To analyse the perspectives of healthcare professionals (HCPs) regarding the acceptance of digital health solutions for growth hormone (GH) deficiency care. This study identified factors impacting HCPs’ intent to use and recommend digital solutions supporting recombinant-human growth hormone (r-hGH) therapy in Italy and Korea with a use case of connected drug delivery system (Aluetta® with Smartdot™) integrated in a platform for GH treatment support (the Growzen™ digital health ecosystem).Methods: Participatory workshops were conducted in Rome, Italy, and Seoul, Korea, to collect the perspectives of 22 HCPs on various predefined topics. HCPs were divided into two teams, each moderated by a facilitator. The workshops progressed in five phases: introduction of the project and experts, capturing views on the current context of digitalisation, perceived usefulness and ease of use of Aluetta® with Smartdot™, exploration of the perception of health technology evolution, and combined team recommendations. Data shared by HCPs on technology acceptance were independently analysed using thematic analysis, and relevant findings were shared and validated with experts.Results: HCPs from both Italy and Korea perceived Aluetta® with Smartdot™ and the Growzen™ based digital health ecosystem as user-friendly, intuitive, and easy-to-use solutions. These solutions can result in increased adherence, a cost-effective healthcare system, and medication self-management. Although technology adoption and readiness may vary across countries, it was agreed that using digital solutions tailored to the needs of users may help in data-driven clinical decisions and strengthen HCP–patient relationships.Conclusion: HCPs’ perspectives on the digitalisation in paediatric GH therapies suggested that digital solutions enable automatic, real-time injection data transmission to support adherence monitoring and evidence-based therapy, strengthen HCP–patient relationships, and empower patients throughout the GH treatment process.


  • Open Access

    THU163 Traffic Light Alerting System For Adherence Risk Management To Improve Catch-Up Growth In Patients Receiving Recombinant Human Growth Hormone Therapy

    by Sandro Loche, Paula van Dommelen, Ekaterina Koledova

    Disclosure: S. Loche: Advisory Board Member; Self; SL has received advisory board fees from the healthcare business of Merck KGaA, Darmstadt, Germany. Consulting Fee; Self; SL has received consultancy fees from the healthcare business of Merck KGaA, Darmstadt, Germany. Speaker; Self; SL has received lecture fees from the healthcare business of Merck KGaA, Darmstadt, Germany. P. van Dommelen: Consulting Fee; Self; PvD has a consultancy agreement with the healthcare business of Merck KGaA, Darmstadt, Germany. E. Koledova: Employee; Self; EK is an employee of the healthcare business of Merck KGaA, Darmstadt, Germany. Stock Owner; Self; EK holds shares in the healthcare business of Merck KGaA, Darmstadt, Germany. Background: In our previous study, a data-driven clinical decision support system based on “traffic light” visualizations for adherence risk management in patients receiving recombinant human growth hormone (r-hGH) treatment was developed.1 Two “traffic lights” were most promising: mean adherence and standard deviation (SD) of hours to next injection (administering injections at around the same time each day). We aimed to study the effect of these two adherence-based traffic lights on catch-up growth in the first year of treatment in patients with growth hormone deficiency (GHD) and those born small for gestational age (SGA). Data and Methods: Height and adherence data were extracted from the easypod™ connect ecosystem and taken from the easypod™ connect observational study.2 Patients with: height standard deviation scores (HSDS) of ≤-2 at treatment start; age 2-15 years at treatment start; and ≥1 measurement and adherence data available in the first year of treatment, were selected. Mean adherence was classified as high (≥85%), intermediate (>56%-Results: In total, data for 1,045 patients (776 and 269 with GHD and those born SGA, respectively) were available. Only some of the adherence-based categories had a significant and independent effect on ΔHSDS (P=0.004). Adjusted for age and HSDS at treatment start, patients with high/intermediate mean adherence had, on average, a +0.15 SD higher ΔHSDS (P=0.004), while this was +0.09 SD for patients with a low SD of hours to the next injection (P=0.003). Therefore, patients with both high/intermediate mean adherence and a low SD of hours to the next injection had, on average, a +0.24 SD higher ΔHSDS compared with patients with both low mean adherence and a high SD of hours to the next injection. Conclusions: Our research shows that good adherence and administering injections around the same time each day play an essential role in optimizing catch-up growth. Adherence-based traffic lights can alert clinicians to have discussions with patients/caregivers to mitigate the risk of sub-optimal adherence and, consequently, improve catch-up growth. References: 1. Araújo M, et al. Stud Health Technol Inform 2021;287:23-7; 2. Koledova E, et al. Endocr Connect 2018;7:914-23. Presentation: Thursday, June 15, 2023

  • Open Access

    Evaluating the Usefulness and Ease of Use of a Next-Generation–Connected Drug Delivery Device for Growth Hormone Therapy: Qualitative Study of Health Care Professionals’ Perceptions

    by José I Labarta, Paul Dimitri, Matthew Keiser, Ekaterina Koledova, Octavio Rivera-Romero

    Background: Digital solutions targeting children’s health have become an increasingly important element in the provision of integrated health care. For the treatment of growth hormone deficiency (GHD), a unique connected device is available to facilitate the delivery of recombinant human growth hormone (r-hGH) by automating the daily injection process and collecting injection data such that accurate adherence information is available to health care professionals (HCPs), caregivers, and patients. The adoption of such digital solutions requires a good understanding of the perspectives of HCPs as key stakeholders because they leverage data collection and prescribe these solutions to their patients. Objective: This study aimed to evaluate the third generation of the easypod device (EP3) for the delivery of r-hGH treatment from the HCP perspective, with a focus on perceived usefulness and ease of use. Methods: A qualitative study was conducted, based on a participatory workshop conducted in Zaragoza, Spain, with 10 HCPs experienced in the management of pediatric GHD from 7 reference hospitals in Spain. Several activities were designed to promote discussion among participants about predefined topics based on the Technology Acceptance Model and the Unified Theory of Acceptance and Use of Technology to provide their perceptions about the new device. Results: Participants reported 2 key advantages of EP3 over previous easypod generations: the touch screen interface and the real-time data transmission functionality. All participants (10/10, 100%) agreed that the new device should be part of a digital health ecosystem that provides complementary functionalities including data analysis. Conclusions: This study explored the perceived value of the EP3 autoinjector device for the treatment of GHD by HCPs. HCPs rated the new capabilities of the device as having substantial improvements and concluded that it was highly recommendable for clinical practice. EP3 will enhance decision-making and allow for more personalized care of patients receiving r-hGH.


  • Open Access

    An Augmented Reality Mobile App (Easypod AR) as a Complementary Tool in the Nurse-Led Integrated Support of Patients Receiving Recombinant Human Growth Hormone: Usability and Validation Study

    by Rosa Maria Baños, Laura-Maria Peltonen, Blaine Martin, Ekaterina Koledova

    Background: Children with growth hormone deficiency face the prospect of long-term recombinant human growth hormone (r-hGH) treatment requiring daily injections. Adherence to treatment is important, especially at treatment initiation, to achieve positive health outcomes. Historically, telenursing services embedded in patient support programs (PSPs) have been a valid approach to support r-hGH treatment initiation and patient education and facilitate adherence by identifying and optimizing appropriate injection techniques. The development of mobile phones with augmented reality (AR) capabilities offers nurses new tools to support patient education. Objective: To investigate experiences among nurses of a new mobile phone app developed to support patient training with a phone-based PSP for r-hGH treatment. Methods: In 2020, the Easypod AR mobile app was launched to support nurse-driven telehealth education for patients initiating r-hGH therapy with the Easypod electromechanical auto-injector device. Nurses who were part of PSPs in countries where the Easypod AR app had been launched or where training was provided as part of an anticipated future launch of the app were invited to participate in an online survey based on the Mobile App Rating Scale to capture their feedback after using the app. Results: In total, 23 nurses completed the online questionnaire. They positively rated the quality of the app across multiple dimensions. The highest mean scores were 4.0 for engagement (ie, adaptation to the target group; SD 0.74), 4.1 (SD 0.79) for functionality (navigation) and 4.1 (SD 0.67) for aesthetics (graphics). Responses indicated the potential positive impact of such a tool on enhancing patient education, patient support, and communication between patients and PSP nurses. Some participants also suggested enhancements to the app, including gamification techniques that they felt have the potential to support the formation of positive treatment behaviors and habits. Conclusions: This study highlights the potential for new digital health solutions to reinforce PSP nurse services, including patient education. Future studies could explore possible correlations between any behavioral and clinical benefits that patients may derive from the use of such apps and how they may contribute to support improved patient experiences and treatment outcomes.